Leading manufacturer of external medications, Xiaofang Pharmaceutical, listed on the Shanghai Stock Exchange today with a stock code of 603207. The company's stock was issued at a price of 12.47 yuan per share. Its main business is the research, production, and sales of external medications. Established in 2002, the company has continuously used the well-known "Xinlong" trademark, and its various external medication products have maintained a leading position in the domestic market with a stable therapeutic effect, gaining widespread recognition from patients. In terms of finance, benefiting from the continuous improvement of product awareness, the company's sales have maintained a fast growth trend. The compound annual growth rates of revenue and net income attributable to the parent company for the years 2021-2023 are 8.37% and 26.99% respectively. For the years 2021-2023, Xiaofang Pharmaceutical's gross margin for its main business was 63.31%, 59.00%, and 65.44% respectively. The funds raised by Xiaofang Pharmaceutical this time will be invested in projects such as the construction of a new production base for external medications, the development of new products, the establishment of a marketing system, and brand promotion.